Interleukin (IL)-15 plays an important role in natural killer (NK) and CD81 T-cell proliferation and function and is more effective than IL-2 for tumor immunotherapy. The trans-presentation of IL-15 by neighboring cells is more effective for NK cell activation than its soluble IL-15. In this study, the fusion protein dsNKG2D-IL-15, which consisted of two identical extracellular domains of human NKG2D coupled to human IL-15 via a linker, was engineered in Escherichia coli. DsNKG2D-IL-15 could efficiently bind to major histocompatibility complex class I chain-related protein A (MICA) of human tumor cells with the two NKG2D domains and trans-present IL-15 to NK or CD81 T cells. We transplanted human gastric cancer (SGC-7901) cells into nude mice and mouse melanoma cells with ectopic expression of MICA (B16BL6-MICA) into C57BL/6 mice. Then, we studied the anti-tumor effects mediated by dsNKG2D-IL-15 in the two xenografted tumor models. Human dsNKG2D-IL-15 exhibited higher efficiency than IL-15 in suppressing gastric cancer growth. Exogenous human dsNKG2D-IL-15 was centrally distributed in the mouse tumor tissues based on in vivo live imaging. The frequencies of human CD561 cells infiltrated into the tumor tissues following the injection of peripheral blood mononuclear cells into nude mice bearing human gastric cancer were significantly increased by human dsNKG2D-IL-15 treatment. Human dsNKG2D-IL-15 also delayed the growth of transplanted melanoma (B16BL6-MICA) by activating and recruiting mouse NK and CD81 T cells. The anti-melanoma effect of human dsNKG2D-IL-15 in C57BL/6 mice was mostly decreased by the in vivo depletion of mouse NK cells. These data highlight the potential use of human dsNKG2D-IL-15 for tumor therapy. Cellular & Molecular Immunology
INTRODUCTION
Interleukin (IL)-15 plays an important role in the development, activity, and persistence of natural killer (NK) and CD8
1 T cells, indicating that it has great potential to promote anti-tumor immune responses.
1,2 Unlike IL-2, IL-15 does not seem to be involved in the apoptosis of activated effector CD8
1 T cells and the induction of CD4 1 CD25 1 Foxp3 1 regulatory T cells. 3, 4 Furthermore, preclinical studies suggest that IL-15 is less toxic than IL-2. 5 Previous studies have investigated the anti-tumor activities mediated by membrane-bound IL-15 on NK cells, 6 adenovirus-mediated IL-15 gene transfer, 7, 8 or generation of IL-15 and IL-15 receptor alpha fusion proteins to trans-present IL-15.
9,10 IL-15 is among the top listed agents considered by the National Cancer Institute to have high potential for cancer immunotherapy.
11
IL-15 binds to IL-15Ra with high affinity and forms a complex that shuttles from the endoplasmic reticulum to the cell surface, particularly on monocytes and dendritic cells. IL-15Ra trans-presents IL-15 to the IL-2/15Rbc common receptor expressed on neighboring cells, although cis-presentation is also possible. 12, 13 Trans-presentation of IL-15 is required for the maintenance of several lymphoid cell subsets, such as natural killer, natural killer T, and memory CD8 1 T cells. 14, 15 The relevance of IL-15 trans-presentation for an efficient antitumor response has been demonstrated in mouse models with IL-15Ra-transfected MC38 tumor cells 16 and the use of soluble complexes of recombinant IL-15 with IL-15Ra, 17 soluble IL-15 with IL-15Ra-IgG1-Fc complexes, 18 anti-IL-15 fusion proteins, 19 and anti-IL-15Ra sushi domain-IL-15 fusion proteins. 10, 20 The soluble complexes and the fusion proteins were much more stimulatory than IL-15 alone.
NKG2D is an important activating receptor that is widely expressed on NK, CD8
1 T, NKT, cdT, and some CD4 1 T cells. Following ligation to DAP10 or DAP12, NKG2D induces cytotoxicity and IFN-c production by NK cells and costimulation of T-cell functions. Major histocompatibility complex class I chain-related protein A/B (MICA/MICB) and the UL-16 binding protein are NKG2D ligands in humans. 21, 22 These ligands are preferentially expressed on stress-induced cells or tumor cells and are not found in most normal tissues. 23, 24 A biofunctional fusion protein (scFv-NKG2D) that binds tumor cells through NKG2D and recruits and stimulates T cells through an anti-CD3 single-chain variable fragment can significantly suppress tumor growth and efficiently induce immune memory. 25 Thus, NKG2D ligands can serve as targets in tumortargeted treatments.
We previously generated a mouse dsNKG2D-IL-15 (mdsNKG2D-IL-15) fusion protein, 26 but the trans-presentation of fused dsNKG2D-IL-15 by neighboring cells and the biodistribution of dsNKG2D-IL-15 in tumor-bearing mice was not fully elucidated. In this study, a human dsNKG2D-IL-15 (hdsNKG2D-IL-15) protein in which two identical extracellular human NKG2D domains were fused to the N-terminus of human IL-15 was generated. Because human NKG2D was not able to bind RAE-1 (the MICA homologue in mice) and other ligands of mouse NKG2D, 25 we characterized the activation of human NK cells by hdsNKG2D-IL-15 trans-presented by neighboring cells ex vivo and the activities of hdsNKG2D-IL-15 against xenografted human gastric cancers in nude mice. B16BL6-MICA cells were also transplanted into normal C57BL/6 mice, and the bio-distribution of hdsNKG2D-IL-15, its anti-melanoma activity, and its activation of NK and CD8
1 T cells was evaluated in tumor-bearing mice.
MATERIALS AND METHODS

Materials
The plasmid containing the human NKG2D cDNA sequence was provided by Prof. L. L. Lanier of UCLA, and the pORF-hIL-15 plasmid was purchased from In vivo Gen (San Diego, CA, USA). Escherichia coli strain M15 and the pQE31 plasmid were obtained from Qiagen (Dusseldorf, Germany). Taq DNA polymerase, restriction endonucleases, T4 DNA polymerase, PCR product purification kits, and DNA recovery kits were all purchased from Takara Bio (Dalian, China). Ni 1 -NTA purification columns were obtained from Qiagen (Dusseldorf, Germany). Recombinant human NKG2D-Ig and the NKG2A antibody (FAB1059A) were purchased from R&D Systems (Boston, MA, USA). Recombinant human IL-15 was obtained from Peprotech (Rocky Hill, NJ, USA).The IL-15 polyclonal antibody (pAb) H-114 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The IL-15 conformational monoclonal antibody (mAb) (Ab55276) with or without fluorescent labeling was from Abcam (Cambridge, MA, USA). Antibodies against human MICA (6D4), CD56 (MEM-188), CD16 (CB16), NKG2D (1D11), CD69 (FN50), IFN-c (4SB3), CD107a (H4A3), NKp46 (9E2), CXCR3 (TG1), and DNAM-1 (11A8) were obtained from BioLegend (San Diego, CA, USA). Antibodies against mouse NK1.1 (PK136), NKG2D (CX5), CD122 (TU27), and CD8 (53.67) were also from BioLegend. Secondary antibodies conjugated to horseradish peroxidase (HRP) or a fluorophore were obtained from Invitrogen (Grand Island, NY, USA). The K562, HeLa, and B16BL6 cell lines were all from ATCC. The human gastric cancer cell line SGC-7901 was obtained from the Chinese Academy of Science. MICA was ectopically expressed on K562 27 or B16BL6 28 cells as previously described.
Construction of the recombinant hdsNKG2D-IL-15 plasmid
The genetic sequences encoding the human NKG2D extracellular domain (Phe78-Val 216) were amplified with two different pairs of primers to generate two NKG2D fragments with different tail sites for restriction enzyme recognition. The sequence of the first primer pair was 59-CTGGATCCGTTCCTAAACTCATTATTC AACCAAG and 39-CGAGGCCTAGATCCGCCGCCTCCTG AACCGCCACCTCCTGAGCCGCCTCCGCCTGAGCCA CCGCCTCCCACAGTCCTTTGCATGCAGATGTAC, and the sequence of the second primer pair was 59-CTAGGCCTTT CCTAAACTCATTATTCAACCAAG and 39-CTCTGCAGA GATCCGCCGCCTCCTGAACCGCCACCTCCTGAGCCGC-CTCCGCCTGAGCCACCGCCTCCCACAGTCCTTTGCATG CAGATGTAC. Two NKG2D gene segments were sequentially inserted into pQE31. The primers for human IL-15 amplification (Asn 49-Ser 162) were forward: 59-CTCTGCAGAA CTGGGTGAATGTAATAAGTGATT and reverse: 39-CG AAGCTTTCAAGAAGTGTTGATGAACATTTGG. The IL-15 gene fragment was inserted into the pQE31 plasmid downstream from the two NKG2D domains. The primers introduced the recognition sites for the restriction enzymes BamH I, Stu I, Pst I, and Hind III. Flexible linkers were inserted between the three domains. The mdsNKG2D-IL-15 protein was generated as described previously.
Generation of the hdsNKG2D-IL-15 protein
The fusion protein was produced in bacteria as an inclusion body after IPTG induction. The inclusion body was isolated and dissolved in urea. The recombinant protein was purified using two Ni 1 -NTA columns and renatured in a solution of 400 mM L-arginine, 5 mM reduced glutathione, 0.5 mM oxidized glutathione, 100 mM Tris-HCl, 2 mM ethylenediaminetetraacetic acid, 10% glycerin, 0.2 mM phenylmethanesulfonyl fluoride, 0.7 mg mL 21 pepstatin A, and 0.5 mg mL 21 leupeptin. Then, the protein solution was replaced with PBS. Prior to use, LPS was removed from the recombinant protein samples on and a polymyxin B-modified resin column obtained from GenScript (Nanjing, China). The endotoxin concentration of each sample was below 0.06 EU mL 21 in Limulus amebocyte lysate tests.
Western blotting
The recombinant human hdsNKG2D-IL-15 protein at 1:1, 1:2, or 1:5 dilutions was separated on 1-mm-thick 5-12% Trisglycine gels and then transferred to a polyvinylidene fluoride (PVDF) membrane. The PVDF membranes were blocked with 5% (w/v) nonfat dry milk powder in Tris-buffered saline and Tween 20 (TBST) buffer. The anti-NKG2D pAb (Ab96606, Abcam) or anti-IL-15 pAb (Ab134177, Abcam) was diluted 1:500 in TBST buffer containing 2 mg mL 21 BSA and incubated with the membrane for 2 h at 37uC. Then, the PVDF membranes were incubated with HRP-conjugated goat antirabbit IgG (1:3000 in TBST) (Invitrogen) for 1 h. The membranes were washed extensively with TBST, and immune reactive bands were visualized with a chemiluminescence reagent (Dakewe, Shenzhen, P.R. China).
Enzyme-linked immunosorbent assay (ELISA)
The human NKG2D and IL-15 domains of hdsNKG2D-IL-15 were identified by ELISA assays. Briefly, bovine serum albumin (BSA), human dsNKG2D-IL-15 (1 mg), human NKG2D-Ig (1 mg), and recombinant human IL-15 (1 mg) were coated onto polystyrene foam wells overnight. The primary antibody (10 mg mL 21 ) against either NKG2D or IL-15 was added, and then a secondary antibody (1 mg mL
21
) labeled with HRP was added to the plate. Binding of hdsNKG2D-IL-15 to MICA was confirmed after initially coating the recombinant soluble MICA protein (1 mg) on the wells. Different concentrations of hdsNKG2D-IL-15 (5, 10, and 20 mg mL 21 ) were added to the plate. Then, the IL-15 antibody and HRP-secondary antibodies were added to the wells. The OD 450 value was read after adding the substrate and stop solution to the wells.
Competition assay B16-MICA or B16 mock-transfected cells were incubated with 0, 1, 2, 5, or 10 mg mL 21 of human or mouse dsNKG2D-IL-15 at 37uC for 1 h. The cells were collected and washed with PBS. Next, commercial recombinant human NKG2D-Ig (5 mg mL
) was incubated with these cells at 37uC for another hour. After washing, the cells were stained with fluorescent goat anti-human IgG antibody for 30 min and detected by flow cytometry.
NK cell proliferation
The MTS/PMS assay (Promega, Madison, WI, USA) was used to detect the proliferation of NK cells. NK cells were sorted from peripheral blood mononuclear cells (PBMCs) using a magnetic bead-labeled CD56 antibody (Miltenyi, Germany). The cells were cultured with recombinant soluble human dsNKG2D-IL-15 (10 ng mL 21 ), immobilized dsNKG2D-IL-15 that was coated on plates (2 mg), or commercialized soluble IL-15 (10 ng mL
21
). A sample of NK cells that were cultured alone was used as a control, and the samples were run in triplicate. The MTS/PMS solution was added to each well on day 3. After 4 h, the absorbance was read at 490 nm.
Detection of cytotoxicity NK cell cytotoxicity was determined by assessing CD107a expression on NK cells or by performing a lactate dehydrogenase (LDH) release assay. PBMCs were mixed with K562 cells at ratios of 3:1, 1:1, and 1:3. Either fluorochrome-conjugated anti-CD107a mAb or an isotype control antibody was added to the mixture for CD107a staining. After 2 h, monensin (GolgiStop; BD Biosciences, San Jose, CA, USA) was added at a 1:100 dilution and incubated for another 2 h. Surface staining was achieved by incubating the cells with an anti-CD56 mAb on ice for 30 min. The cells were washed, re-suspended in PBS, and immediately analyzed by flow cytometry. We assessed the cytotoxicities of NK cells by co-culturing the NK cells with target cells for 4 h and then estimating the cytotoxicity in LDH release assays according to the manufacturer's protocol.
Intracellular staining IFN-c production was assessed with an intracellular staining kit (eBioscience, San Diego, CA, USA). Briefly, PBMCs were cultured with soluble dsNKG2D-IL-15, immobilized dsNKG2D-IL-15, or soluble IL-15 in the presence of brefeldin A (10 mg mL
; eBioscience, San Diego, CA, USA) at 37uC for 4 h. Then, the NK cells were stained with an anti-CD56 mAb by incubating at 4uC for 30 min. The cells were fixed and permeabilized at room temperature for 20 min. The permeabilized cells were stained with either a PE-labeled anti-IFN-c mAb or the isotype antibody and analyzed by flow cytometry.
Mouse tumor models
We subcutaneously implanted SGC-7901 cells (n 5 6, 2 3 10 6 cells) into the backs of nude mice. Human dsNKG2D-IL-15 (60 mg), mdsNKG2D-IL-15 (60 mg), recombinant human IL-15 (60 mg) or PBS was intraperitoneally injected daily into these mice from days 5 to 20.Tumor growth was measured using digital calipers, and the tumor volume was calculated as V 5 (width) 2 3 length/2. All mice were killed on day 21 for the collection of their spleens and tumors. To evaluate the survival of tumor-bearing mice, we also implanted SGC-7901 cells (n 5 6, 2 3 10 6 cells) into the backs of nude mice treated with recombinant proteins or PBS, Mouse viability was recorded daily.
To create B16BL6 cell-transplanted tumor mice, B16BL6 or B16BL6-MICA cells were subcutaneously injected into C57BL/ 6 mice (n 5 6, 2 3 10 6 cells). Human dsNKG2D-IL-15 (60 mg), mdsNKG2D-IL-15 (60 mg), or PBS were intraperitoneally injected daily into these mice from days 5 to 21.Tumor growth was measured daily. All mice were killed on day 22, and their spleens were collected. All experiments were conducted in accordance with the protocols approved by the Institutional Animal Care and Use Committee of Yangzhou University.
In vivo distribution of human dsNKG2D-IL-15
Human dsNKG2D-IL-15 was labeled with cyanine dye 5. 
Isolation of lymphocytes from tumor tissues
Tumor samples from nude mice were finely grounded, digested with collagenase type III (100 mg mL 21 ), dispase (550 mg mL 21 ), and DNase I (300 mg mL
21
) for 4-6 h and sieved through 70 mm and 40 mm pore strainers. The cell suspensions were centrifuged and treated with Tris-NH 4 Cl to remove red blood cells. The lymphocytes were isolated by centrifugation in a 35% Percoll solution. Lymphocyte suspensions were incubated with mAbs against NK1.1 and NKG2D and detected by flow cytometry.
In vivo depletion of NK and CD8
1 T cells A rabbit polyclonal anti-asialo-GM1 antibody (100 mg) was intraperitoneally injected into C57BL/6 mice or nude mice every 3 days. The injection started 3 days prior to the injection of B16BL6-MICA cells or SGC-7901 cells and lasted throughout the course of the experiment. Similarly, an anti-CD8 antibody (clone 2.43, 200 mg) was repeatedly injected into mice (once per week) to remove CD8 1 T cells. Cell depletion was occasionally monitored by analyzing PBMCs by flow cytometry using an NK1.1 or CD8 marker.
Statistical analysis
Differences between the groups were analyzed using Student's t-test. Analysis of variance was performed to determine the different effects of various treatment groups. Kaplan-Meier survival curves were plotted and analyzed with GraphPad Prism software. P , 0.05 was considered statistically significant.
RESULTS
Binding of human dsNKG2D-IL-15 to MICA
The schematic structure of human dsNKG2D-IL-15 is shown in Supplementary Figure 1a . The recombinant pQE31-hdsNKG2D-IL-15 plasmid was verified by restriction digestion (Supplementary Figure 1b) .The purified human dsNKG2D-IL-15 protein was a monomer approximately 43 kD in size (both before and after renaturation), which was consistent with the expected size (Supplementary Figure 1c) . The NKG2D and IL-15 domains in human dsNKG2D-IL-15 were identified by binding to their corresponding antibodies in a western blot assay ( Figure 1a ). Two indirect ELISA assays were developed to determine whether the NKG2D and IL-15 domains of dsNKG2D-IL-15 had a normal structure after renaturation. The antibody against human NKG2D bound to both the recombinant hdsNKG2D-IL-15 and human NKG2D-Ig proteins but did not bind to BSA. The IL-15 antibody bound to hdsNKG2D-IL-15 and human IL-15 but did not bind to BSA (Figure 1b) . Thus, the recombinant hdsNKG2D-IL-15 protein generated in E. coli was efficiently renatured in vitro.
The binding of hdsNKG2D-IL-15 to the NKG2D ligand MICA was measured by a sandwich ELISA assay. DsNKG2D-IL-15 efficiently bound to MICA-coated plates because the addition of the IL-15 antibody or NKG2D polyclonal antibody led to significantly enhanced absorbance in a dose-dependent manner. The lack of binding of the NKG2D monoclonal antibody to dsNKG2D-IL-15 that was pre-associated with platebound MICA may be attributed to the fact that the same We used a melanoma cell line (B16-MICA) in which MICA was ectopically expressed 28 to verify human dsNKG2D-IL-15 binding to cell membrane-bound MICA via the NKG2D domain. B16-MICA cells were pre-incubated with human or mouse dsNKG2D-IL-15, stained with a rabbit pAb against both human and mouse IL-15, and detected using a fluorescent goat anti-rabbit antibody. As expected, human dsNKG2D-IL-15 bound strongly to B16-MICA cells, while mouse dsNKG2D-IL-15 bound weakly to the same cells. When B16-MICA cells were pre-incubated with a MICA antibody, neither human nor mouse dsNKG2D-IL-15 could bind to the B16-MICA cells (Figure 1e ). Human and mouse dsNKG2D-IL-15 could not bind to mock-transfected B16 cells (Supplementary Figure 4) . Similarly, the NKG2D mAb could not bind to 
Human dsNKG2D-IL-15 proteins efficiently activate NK cells in vitro
We assessed the ability of hdsNKG2D-IL-15 to activate NK cells in vitro. Similar to IL-15, both soluble and immobilized hdsNKG2D-IL-15 stimulated human CD56 1 cells to increase CD69 expression. After a 1-h incubation, only immobilized hdsNKG2D-IL-15 weakly promoted CD56 1 cells to express NKG2D. After a 12-h incubation, both soluble and immobilized hdsNKG2D-IL-15 and rhIL-15 all weakly enhanced NKG2D expression (Figure 2a, Supplementary Figure 5a) . The cytotoxicities of NK cells against K562, HeLa, and SGC-7901 cells that were pre-stimulated with soluble hdsNKG2D-IL-15, immobilized hdsNKG2D-IL-15, or IL-15 were compared. Both the soluble and immobilized hdsNKG2D-IL-15 proteins highly promoted the killing of the activity, IFN-c production, and proliferation of NK cells (Figure 2b-d) . Additionally, immobilized hdsNKG2D-IL-15 displayed more stimulatory effects (Figure 2a-d) .
To confirm that the activation of CD56 1 cells by immobilized hdsNKG2D-IL-15 was mediated by the IL-15 domain, an IL-15 conformational antibody was added to wells pre-coated with hdsNKG2D-IL-15 and cultured with human PBMCs overnight. CD69 expression was significantly decreased as compared with stimulation with immobilized hdsNKG2D-IL-15. Additionally, the enhanced expression of CD69 by immobilized hdsNKG2D-IL-15 was completely blocked when an IL-15 receptor b antibody was added to cultured human PBMCs and simultaneously stimulated with immobilized hdsNKG2D-IL-15 ( Figure 2e ).
Some NK cell receptors were characterized after stimulation with either soluble or immobilized hdsNKG2D-IL-15. As expected, both forms of the hdsNKG2D protein upregulated 1 cells with soluble or plate-bound dsNKG2D-IL-15 stimulation were detected using flow cytometry. *P , 0.05 versus medium, **P , 0.01 versus medium.
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NKp46, NKG2A, and CXCR3 expression on CD56 1 cells but exhibited no effects on DNAM-1 and CD16 expression levels (Figure 2f, Supplementary Figure 5b) 
Human dsNKG2D-IL-15 inhibits transplanted gastric cancer in nude mice
There is 70% identity between the human and mouse IL-15 proteins. Both human and mouse IL-15 activate mouse NK cells, but mouse IL-15 poorly stimulates human NK cells.
29,30
Human dsNKG2D-IL-15 bound to SGC-7901 cells efficiently, whereas mouse dsNKG2D-IL-15 did not exhibit similar binding activity (Figure 4a) . Here, the recombinant mouse dsNKG2D-IL-15 protein was regarded as a soluble form of mouse IL-15 because mouse NKG2D did not bind to the ligands of human NKG2D 
Anti-tumor activity of hdsNKG2D-IL-15 mostly depends on NK cells
We analyzed the anti-tumor activity and the cellular mechanisms of human dsNKG2D-IL-15 in normal C57BL/6 mice. B16BL6-MICA and B16BL6 cells were subcutaneously transplanted into C57BL/6 mice. Then, the human and mouse dsNKG2D-IL-15 proteins were intraperitoneally injected into the tumor-bearing mice. Human dsNKG2D-IL-15 and mdsNKG2D-IL-15 both suppressed tumor growth in the 1 NK cells in tumor tissues (e) and spleens (f) from cancer-bearing mice on day 21, as determined by flow cytometry (n 5 4). *P , 0.05, **P , 0.01, ns means no significance. The experiments were performed twice.
B16BL6-MICA cell-transplanted mice, but human dsNKG2D-IL-15 played a more significant role. In the B16BL6 cell-transplanted mice, the two recombinant proteins mediated similar effects in the retardation of tumor growth (Figure 6a ). The tumor-bearing mice treated with the two types of dsNKG2D-IL-15 also showed no signs of inflammatory damages (e.g., diarrhea, skin rash, and ruffled hair), suggesting an absence of toxicity.
Frequencies of NKG2D 1 NK cells (Figure 6b ), CD8
1 NKG2D 1 T cells, and CD8 1 CD44 1 T cells (Figure 6c ) in the spleen were significantly higher in mice that received human dsNKG2D-IL-15 treatment than in B16BL6-MICA-bearing mice treated with PBS and mdsNKG2D-IL-15. CD44 mediates the recruitment of lymphocytes to sites of inflammation, and its enhanced expression represents cell activation. Only the CD8 1 NKG2D 1 T-cell frequency was enhanced following human or mouse dsNKG2D-IL-15 treatment compared with PBS treatment in the B16-bearing mice (Supplementary Figure  7) . Moreover, when NK cells were depleted in the B16BL6-MICA bearing mice prior to the injection of the recombinant human dsNKG2D-IL-15 protein, the anti-melanoma effects induced by human dsNKG2D-IL-15 were significantly blocked. By contrast, melanoma growth in mice subjected to CD8 1 T-cell depletion was faster only on days 16-18 compared with mice treated with human dsNKG2D-IL-15 alone (Figure 6d) . Thus, NK cell activation by human dsNKG2D-IL-15 was the primary contributor to tumor inhibition in vivo. 1 tumor patients. MICA is a signal of stress and is highly expressed on tumor cells at an early state. 31 Ectopic expression of MICA on tumor cells stimulated NK cell activation and thus promoted antitumor activity. 32, 33 However, the tumor environment is complicated. First, tumor cells with high level expression of MICA or other NKG2D ligands were killed as the tumor developed. Only tumor cells with low-level expression of the NKG2D ligands survived in vivo. 34 Second, MICA was shed from tumor cells by the ADAM protease 35 or metalloproteinases. 36 Serum NKG2D ligands not only competed with the membrane proteins for NKG2D binding but also downregulated NKG2D expression on lymphocytes. 37 Third, the persistent expression of MICA on dendritic cells or tumor cells induced regulatory CD4
1 NKG2D 1 T cells to promote tumor evasion by expressing membrane-bound TGF-b and the Fas ligand. 38, 39 Thus, the human dsNKG2D-IL-15 protein may not only bind to tumor cells but also potentially neutralize serum NKG2D ligands.
The use of dsNKG2D-IL-15 for tumor treatment also has other advantages. The molecular weight of dsNKG2D-IL-15 was ,50 kD, indicating that this molecule could easily penetrate into tumor tissues. Because both the NKG2D and IL-15 domains of dsNKG2D-IL-15 were the same as those of endogenous human NKG2D and IL-15, the fusion protein was weakly immunogenic. IL-15 also upregulated NKG2D expression levels on lymphocytes to promote anti-tumor activity. 40 Furthermore, some pharmaceutical anti-tumor agents (e.g., doxorubicin 41 1 T cells. The stronger anti-tumor effect following injection of human dsNKG2D-IL-15 in B16BL6-MICA-tumor mice was not due to the higher stimulatory activity of human dsNKG2D-IL-15 compared with mdsNKG2D-IL-15. We previously reported that human dsNKG2D-IL-15 was weaker than mdsNKG2D-IL-15 in suppressing tumor growth in CT-26-transplanted tumor mice. 26 Human NK cell migration to the transplanted gastric cancers was regarded as the subsequent event following NK cell activation. Human dsNKG2D-IL-15 stimulates NK cells to produce IFN-c, and IFN-c production by activated NK cells stimulates the secretion of CXCR3 ligands such as IP-10 in tumor cells. 44 Furthermore, both the soluble and membrane-bound dsNKG2D-IL-15 proteins directly upregulated CXCR3 expression on NK cells, as shown in the results (Figure 2e and 3d) .
There was a possibility that dsNKG2D-IL-15 would compete with the interaction of MICA on cancer cells and NKG2D on NK cells and thus downregulate NK cell activation. However, the NKG2D expression level on NK cells was low in advanced tumor patients and NK cell function was generally inhibited. 45 The affinity of IL-15 and its receptor bc (Kd , 10 29 M) 46 was significantly higher than the affinity between Anti-tumor activity of human NKG2D-IL-15 Y Chen et al
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MICA and NKG2D (Kd , 10 26 M). 47 Thus, the addition of IL-15 would be theoretically more effective for NK cell activation in tumor patients than NKG2D ligation. The anti-tumor activity shown by dsNKG2D-IL-15 in our study confirmed the effective activation of NK cells by dsNKG2D-IL-15.
A fusion protein composed of the NH 2 -terminal (amino acids 1-77) sushi domain of IL-15 receptor a coupled via a linker to IL-15 displayed better efficacy than IL-15 in vitro. were intravenously injected into the nude mice. Six hours later, the mice were killed and their spleens and tumor tissues were collected. The frequencies of CD56 1 cells in tumor tissues and spleens were detected by flow cytometry.*P ,0.05, ns means no significance. The experiments were performed three times.
effect compared with the effect induced by an untargeted or RD-missing version of the IL-15 fusion protein. 10, 20 However, whether the addition of the IL-15Ra sushi domain in the dsNKG2D-IL-15 protein also has synergistic effects needs further study.
In conclusion, the recombinant human dsNKG2D-IL-15 protein mediated tumor-specific binding and IL-15 activity. The membrane-bound fusion protein showed stronger effects than IL-15 in vitro and in vivo. Following more detailed pharmacokinetic analysis in vivo, human dsNKG2D-IL-15 could be used as a potential adjuvant to activate NK cells and CD8
1 T cells for tumor therapy. Anti-tumor activity of human NKG2D-IL-15 Y Chen et al
